The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.
Hubert
A
A
Peretz
T
T
Manor
O
O
Kaduri
L
L
Wienberg
N
N
Lerer
I
I
Sagi
M
M
Abeliovich
D
D
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D024682:BRCA2 Protein; D005260:Female; D018703:Founder Effect; D019398:Genes, BRCA1 / Q000235:genetics*; D005799:Genes, Dominant; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics*
D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors; D017430:Prostate-Specific Antigen